WHO ICTRP trial
Dolutegravir plus tenofovir alafenamide as a double-drug regimen in HIV positive…
IRCT20191005044984N1 · Iranian Registry of Clinical Trials (IRCT) · Recruiting
Key facts
| Trial ID | IRCT20191005044984N1 |
|---|---|
| Public title | Dolutegravir plus tenofovir alafenamide as a double-drug regimen in HIV positive patients |
| Scientific title | Comparing efficacy of dolutegravir plus tenofovir alafenamide as dual-drug regimen with the standard triple-drug regimen in HIV positive patients |
| Primary sponsor | Tehran University of Medical Sciences |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Recruiting |
| Study type | interventional |
| Phase | 3 |
| Countries | Iran (Islamic Republic of) |
| Conditions | Virologically Undetectable HIV Patients. |
| Interventions | Intervention 1: Intervention group: The patients' previous standard triple-drug regimen will be changed to the dual-drug regimen including dolutegravir tablet, 50 mg daily plus tenofovir alafenamide tablet, 25 mg daily. This change will be… |
| Registration date | Dec 21, 2019 |
| Target size | 80 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: